1. Chou CW, Huang YK, Kuo TT, Liu JP, Sher YP. An Overview of ADAM9: Structure,
Activation, and Regulation in Human Diseases. Int J Mol Sci. 2020 Oct21;21(20):7790. doi: 10.3390/ijms21207790. PMID: 33096780; PMCID: PMC7590139.
2. Bazzone LE, Zhu J, King M, Liu G, Guo Z, MacKay CR, Kyawe PP, Qaisar N,
Rojas-Quintero J, Owen CA, Brass AL, McDougall W, Baer CE, Cashman T, Trivedi
CM, Gack MU, Finberg RW, Kurt-Jones EA. ADAM9 promotes type I interferon-
mediated innate immunity during encephalomyocarditis virus infection. Nat
Commun. 2024 May 16;15(1):4153. doi: 10.1038/s41467-024-48524-6. PMID: 38755212;PMCID: PMC11098812.
3.Umeda M, Yoshida N, Hisada R, Burbano C, Orite SYK, Kono M, Kyttaris VC,
Krishfield S, Owen CA, Tsokos GC. ADAM9 enhances Th17 cell differentiation and
autoimmunity by activating TGF-β1. Proc Natl Acad Sci U S A. 2021 May
4;118(18):e2023230118. doi: 10.1073/pnas.2023230118. PMID: 33911034; PMCID:
PMC8106302.